Originally published by our sister publication Pharmacy Practice News
A novel topical gel, LUT014 (Lutris Pharma), significantly reduced the severity of the acne-like rash, a common side effect of anti-EGFR (epidermal growth factor receptor) therapies, in patients with colorectal cancer, according to a phase 2 trial.
The study, by researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center, was presented at the